Current opinion in ophthalmology (Curr Opin Ophthalmol)

Publisher: Lippincott, Williams & Wilkins

Journal description

Topics Covered: Cataract Surgery and Lens Implantation; Glaucoma; Retina and Vitreous Disorders; Corneal and External Disorders and Refractive Surgery; Strabismus; Oculoplastic and Orbital Surgery; Neuro-ophthalmology; Ocular Manifestations of Systemic Disease.

Current impact factor: 2.64

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.638
2012 Impact Factor 2.557
2011 Impact Factor 2.647
2010 Impact Factor 2.429
2009 Impact Factor 2.49
2008 Impact Factor 2.958

Impact factor over time

Impact factor
Year

Additional details

5-year impact 0.00
Cited half-life 5.30
Immediacy index 0.35
Eigenfactor 0.01
Article influence 0.00
Website Current Opinion in Ophthalmology website
Other titles Current opinion in ophthalmology (Online), Current opinion in ophthalmology
ISSN 1531-7021
OCLC 36903873
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Lippincott, Williams & Wilkins

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • Pre-print must be removed upon acceptance for publication
    • Post-print may be deposited in personal website or institutional repository
    • Publisher's version/PDF cannot be used
    • Must include statement that it is not the final published version
    • Published source must be acknowledged with full citation
    • Set statement to accompany deposit
    • Must link to publisher version
    • NIH authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 12 months embargo (see policy for details)
    • Wellcome Trust and HHMI authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 6 months embargo (see policy for details)
    • Publisher last reviewed on 19/03/2015
  • Classification
    ‚Äč yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Continued controversy exists regarding intermittent exotropia and its management. Although it has been studied extensively, the indication for and timing of intervention and what therapy is most efficacious remains unclear. This article reviews the most recent research and the controversies surrounding the disease classification and treatment options in the management of intermittent exotropia. Current studies are underway to uncover the natural history of the intermittent exotropia. Patching and observation are reasonable treatment options in the first 6 months of the disease presentation. As the disease progresses and nonsurgical management fails, botulinum toxin may play a role or be an alternative option in the early treatment of intermittent exotropia. Surgical treatment with orthoptic therapy may result in improved postoperative outcomes. Although significant investigations have been performed on this entity, there remains poor cohesiveness between clinical trials resulting in lack of clarity regarding when and how to treat intermittent exotropia. As the natural history of the disease is elucidated and researchers standardize their assessment of the control of the strabismus and what constitutes a successful treatment outcome, better understanding may occur to develop more efficacious remedies. Despite being less known and utilized, botulinum toxin and orthoptic therapy are options for treatment for intermittent exotropia and should be considered for appropriate patient's treatment protocol.
    Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000188
  • Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000194
  • [Show abstract] [Hide abstract]
    ABSTRACT: Given the vast genetic and phenotypic heterogeneity seen in ocular genetic disorders, considering a patient's clinical phenotype in the context of the family history is essential. Clinicians can improve patient care by appropriately incorporating a patient's family history into their evaluation. Obtaining, reviewing, and accurately interpreting the pedigree are skills geneticists and genetic counselors possess. However, with the field of ophthalmic genetics vastly growing, it is becoming essential for ophthalmologists to understand the utility of the pedigree and develop their abilities in eliciting this information. By not considering a patient's clinical history in the context of the family history, diagnoses can be missed or inaccurate. The purpose of this review is to inform ophthalmologists on the importance of the family history and highlight how the pedigree can aid in establishing an accurate genetic diagnosis. This review also provides to ophthalmologists helpful tips on eliciting and interpreting a patient's family history.
    Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000192
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purposes of this article are to examine the literature published on achromatopsia and provide a comprehensive review of the clinical disease, genetic characteristics, and potential for therapy. Specifically, this article will describe recent advances in gene therapy in animal models, clinical features in human, and barriers to human translation. Building on prior success with adeno-associated virus (AAV) therapy in mice models for achromatopsia with mutations in the CNGB3, CNGA3, or GNAT2 genes, multiple cone-specific promoters have recently been developed and shown success in mice and nonhuman primates. A sheep CNGA3 model has also been characterized. Two clinical trials are under way: one to better characterize humans with achromatopsia and another to study a ciliary neurotrophic factor (CNTF) implant as a treatment for patients with the CNGB3 mutation. Genetic understanding and disease characterization of achromatopsia continues to evolve, as do gene therapy tools and animal models. The potential for the treatment of achromatopsia in humans with gene therapy shows great promise.
    Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000189
  • [Show abstract] [Hide abstract]
    ABSTRACT: The decision to stop or continue anticoagulants or antiplatelet therapy for oculoplastic procedures has long been a complicated and serious discussion for surgeons and their patients. Although other specialties have developed evidenced-based algorithms to guide their decision-making our subspecialty remains driven largely by anecdotal information. This article aims to get closer to an evidenced-based approach to perioperative anticoagulant and antiplatelet management. Over the last few years, new antiplatelet and anticoagulant therapies are on the market with different characteristics in terms of half-life and mechanism of action. It is imperative the contemporary surgeon be well versed in these new medications. Also, new studies have emerged from the vascular literature with specific evidenced-based recommendations for heart and stroke patients. These guidelines need to be weighed with a patient's cardiologist or neurologist. The article will review the old and new anticoagulant and antiplatelet therapies as well as the recent literature for stroke and cardiac patients to guide the oculoplastic surgeon in this nuanced decision. It will also discuss current practice patterns in light of these new therapies and medical guidelines.
    Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000187
  • [Show abstract] [Hide abstract]
    ABSTRACT: Brown syndrome is an ocular motility disorder characterized by limited volitional and passive elevation of the eye in adduction. Although originally thought because of abnormalities in the trochlea or tendon sheath (limiting the free movement of the tendon through the trochlea), recent evidence suggests that some cases of congenital Brown syndrome may be related to neurodevelopmental abnormalities of the extraocular muscles (congenital cranial dysinnervation disorders, CCDD). CCDD is a term encompassing congenital abnormalities of eye movements caused by congenital innervational abnormalities. The abnormal development of cranial nerve nuclei or abnormalities in cranial nerve axonal transport affects the development of the extraocular muscle(s). Currently, congenital fibrosis of the extraocular muscles, Duane syndrome, Moebius syndrome, Horizontal gaze palsy and progressive scoliosis, and synergistic divergence are included as CCDDs. In addition, congenial ptosis, Jaw Wink ptosis, and congenital superior oblique palsy are also included. Recently, it has been suggested that some cases of congenital Brown syndrome and congenital superior oblique paresis are related, and these entities may be part of the CCDDs spectrum. Important findings regarding the cause of congenital Brown syndrome will be reviewed.
    Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000191
  • [Show abstract] [Hide abstract]
    ABSTRACT: Autoenucleation has long been described in the literature, dating back as far as the 4th century AD. Within a 3-month period, two patients were admitted to our hospital after autoenucleation. A comprehensive review of the literature was performed to identify trends in, risk factors for, and potential life-threatening complications of autoenucleation. Two adult Caucasian men were transferred from outside hospitals after autoenucleation. One patient's urine tested positive for methamphetamines, and the second patient had a history of schizophrenia. In both cases, imaging of the head and orbits was performed to rule out secondary sequelae after self-enucleation. Patient one did not have any intracranial abnormalities. Patient 2 had a head computed tomography scan that showed a left internal carotid artery dissection, subarachnoid hemorrhage, and basal ganglia/thalamic stroke. Review of the literature revealed that almost all cases were associated with underlying mental illness and/or a history of drug abuse. Autoenucleation occurs more frequently in patients with psychiatric illness or drug abuse. It can be a devastating injury, not only locally, but neurologically. Ophthalmologists should be aware of the potentially life-threatening consequences of autoenucleation.
    Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000184
  • [Show abstract] [Hide abstract]
    ABSTRACT: Oculoplastic genetic diseases can be divided into eyelid, lacrimal, and orbital disorders. The purpose of this review is to develop a rational approach to the categorization of genetic diseases that affect the orbit and review the most recent developments. Genetic disorders that affect the orbit can simply be divided into whether they cause proliferation or arrest of orbital structures. Proliferative conditions include vascular, neural, bony, mesenchymal, and lymphoid. Conditions that cause arrest can be subcategorized into whether they cause soft tissue or bony arrest of development. The genetics of many of these conditions have been elucidated and novel treatments, based on the molecular defects, have been utilized with some success. Molecular advances may result in substitution of a molecular categorization scheme for the one proposed in this manuscript. Delineation of the underlying molecular causes of these disorders will result in earlier, less invasive procedures than those that are currently employed.
    Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000181
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review current surgical practices for the repair of lower eyelid involutional entropion with a focus on recent studies. A shorter axial length, which may be interrelated with exophthalmometry, correlates with involutional entropion. Although it is known Asian eyelids more frequently develop involutional entropion, there is greater awareness of customized surgical approaches. Minimally invasive techniques for strengthening the action of lower eyelid retractors, such as everting sutures and transconjunctival approaches, continue to be refined and studied. Such surgery is efficacious in patients who do not have horizontal laxity. However, there is consistent evidence that in the presence of laxity the recurrence rate is higher if the eyelid is not horizontally tightened. By knowing of the demographics and factors associated with involutional entropion, clinicians can have better understanding of the condition and the patients most at risk. There is not sufficient evidence to determine whether a short axial length is an independent-risk factor for entropion. Advances in surgical technique have led to continued interest in minimally invasive approaches. Precision in addressing individual patients' underlying anatomic abnormalities is important.
    Current opinion in ophthalmology 07/2015; DOI:10.1097/ICU.0000000000000186
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the spectrum of lacrimal gland inflammation, with particular reference to the old condition, idiopathic dacryoadenitis, and the new, immunoglobulin G4 (IgG4)-related dacryoadenitis. Idiopathic dacryoadenitis remains the most common inflammatory lesion of the lacrimal gland, for which surgical treatment is successful. There is mounting evidence that the presence of IgG4-positive plasma cells in a lacrimal gland specimen is nonspecific, for being found in other inflammatory lacrimal gland lesions, even lymphoproliferative ones. To identify IgG4-related dacryoadenitis, particularly when there is no documented disease elsewhere, the criteria have been strengthened toward abundant IgG4-positive plasma cell counting. The gold standard of diagnosis of noninfectious lacrimal gland inflammation is tissue biopsying, which is commonly therapeutic in the case of idiopathic dacryoadenitis. Although it was initially suggested that IgG4-related dacryoadenitis is a possible cause of idiopathic dacryoadenitis, it becomes obvious that it has more resemblance to the lymphoproliferative tumors.
    Current opinion in ophthalmology 07/2015; 26(5):399-407. DOI:10.1097/ICU.0000000000000183
  • [Show abstract] [Hide abstract]
    ABSTRACT: The last two decades have brought advances in materials and manufacturing of large diameter rigid gas-permeable contact lenses, and a greater appreciation of the role of scleral lenses for therapeutic indications. The purpose of this review is to provide an update on the use of rigid gas-permeable scleral lenses in the management of patients with complications after refractive surgery. There are recent reports on clinical experience with specific scleral lens designs from single institutions in cohorts that include patients who have undergone refractive surgery. Typically, these are patients with 'irregular corneas' after radial keratotomy or LASER assisted in-situ keratomileusis, but patients with keratectasia, dry eye syndrome, and corneal neuralgia are also reported. Visual outcomes and wearing success rates are high in these reports, although outcomes for refractive surgery patients are not reported separately. Clinicians who encounter patients with complications after corneal refractive surgery should be aware of advances in scleral lenses. Scleral lenses are an alternative to surgical intervention in patients who might otherwise be considered poor contact lens candidates.
    Current opinion in ophthalmology 07/2015; 26(4):243-248. DOI:10.1097/ICU.0000000000000173
  • [Show abstract] [Hide abstract]
    ABSTRACT: Small-incision lenticule extraction (SMILE) is a novel technique devised to correct refractive errors. SMILE circumvents excimer laser photoablation of cornea, as the stromal lenticule cut by femtosecond laser is removed manually. Smaller incisions and preservation of anterior corneal biomechanical strength have been suggested as some of the advantages of SMILE over femtosecond laser-assisted LASIK (FS-LASIK). In this review, we compared previous published results of SMILE and FS-LASIK. The advantage, efficacy and safety of SMILE are compared with FS-LASIK. SMILE achieved similar efficacy, predictability and safety as FS-LASIK. Greater preservations of corneal biomechanical strength and corneal nerves were observed in SMILE when compared with LASIK or PRK. Additionally, the incidence of postoperative dry eye syndrome was found to be less problematic in SMILE than in FS-LASIK. SMILE is a promising new surgery for refractive error correction. Prospective and retrospective studies of SMILE have shown that results of SMILE are similar to FS-LASIK. With advances in femtosecond laser technology, SMILE may gain greater acceptance in the future.
    Current opinion in ophthalmology 07/2015; 26(4):260-264. DOI:10.1097/ICU.0000000000000158
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the recent advances and reported outcomes in the use of intrastromal corneal ring segments (ICRS) for the treatment of corneal ectasia. ICRS are a well-tolerated and effective treatment for patients with corneal ectasia, particularly keratoconus, offering long-term improvement in visual, refractive, and keratometric measures. ICRS do not consistently decrease corneal aberrations. Patients with mild-to-moderate keratoconus, known to have less predictable outcomes with ICRS, may be better selected and treated with the use of customized nomograms, accounting for factors such as internal astigmatism. Corneal collagen cross-linking performed after ICRS implantation is an important complementary treatment in preventing the progression of ectasia, whereas subsequent treatment with either photorefractive keratectomy or toric intraocular lens implantation offers a significantly improved visual and refractive result. ICRS are an important component to the treatment of corneal ectasia. Knowledge of outcomes among specific groups of patients should improve treatment planning and nomograms. Combined treatments with ICRS allow for notable improvements in corneal stability and refractive error, in addition to the improvement in irregular astigmatism seen with ICRS.
    Current opinion in ophthalmology 07/2015; 26(4):273-277. DOI:10.1097/ICU.0000000000000163
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this review is to offer a comprehensive overview of the different PresbyLASIK approaches, which have been published in peer-reviewed journals. Comprehensive search was conducted in scopus using keywords presbyLASIK, presbyopia, LASIK, corneal multifocality. We reviewed binocular uncorrected and corrected distance and near visual acuity, and loss of lines of best corrected visual acuity, for presbyopic patients among three different basic treatment modalities. Additional trials and standards for reporting results for presbyopic approaches are necessary. Careful patient selection and counseling is imperative in all PresbyLASIK treatments.
    Current opinion in ophthalmology 07/2015; 26(4):265-272. DOI:10.1097/ICU.0000000000000162
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dry eye syndrome can be difficult to manage in severe or refractory cases. In patients in whom traditional treatments have limited efficacy, alternative treatments may be considered for dry eye syndrome, including scleral lenses. The present review summarizes the evidence regarding scleral lens use in dry eye syndrome. Scleral lenses have become a viable option for severe dry eye syndrome, and have been shown to be efficacious and well tolerated, with most reports citing improved visual acuity and relief of symptoms. Currently, there are 18 manufacturers of scleral lenses, although published reports on scleral lenses primarily focus on the BostonSight PROSE and the Jupiter Lens. Scleral lenses are efficacious and well tolerated for use in severe dry eye syndrome. Further research is needed to compare different sizes and types of lenses, and to standardize outcome measures.
    Current opinion in ophthalmology 07/2015; 26(4):319-324. DOI:10.1097/ICU.0000000000000171
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review examines the economic history of refractive surgery and the decline of laser-assisted in-situ keratomileusis (LASIK) in the USA, and the emergence of refractive cataract surgery as an area of growth. Since it peaked in 2007 at 1.4 million procedures per year, LASIK has declined 50% in the USA, whereas refractive cataract surgery, including presbyopia-correcting intraocular lenses (IOLs), astigmatism-correcting IOLs, and femtosecond laser-assisted cataract surgery, has grown to 350 000 procedures per year, beginning in 2003. Patients are price-sensitive and responsive to publicity (good or bad) about refractive surgery and refractive cataract surgery. LASIK's decline has been partially offset by the emergence of refractive cataract surgery. About 11% of all cataract surgery in the USA involves presbyopia-correcting IOLs, astigmatism-correcting IOLs, or a femtosecond laser. From the surgeon's perspective, there are high barriers to entry into the marketplace for refractive surgery and refractive cataract surgery due to the high capital cost of excimer and femtosecond lasers, the high skill level required to deliver spectacular results to demanding patients who pay out of pocket, and the necessity to perform a high volume of surgeries to satisfy both of these requirements. Probably, less than 7% of US cataract surgeons can readily meet all of these requirements.
    Current opinion in ophthalmology 07/2015; 26(4):249-254. DOI:10.1097/ICU.0000000000000159
  • [Show abstract] [Hide abstract]
    ABSTRACT: Surgical treatment has been the accepted mode of treatment for infantile esotropia for decades. The present review of recent literature evaluates the current standing of: type of surgery performed and best timing of surgery to achieve optimal results. Recent studies suggest that early surgical intervention is of benefit by improving the probability of developing stereopsis. A significant advantage of the type of surgical intervention has yet to be demonstrated by the current studies. Botulinum toxin continues to be used for treatment of infantile esotropia, although it has not been shown to be a superior treatment. Although many theories exist, the true cause of infantile esotropia remains unknown. The literature suggests that treatment before age 2 and perhaps even earlier improves the potential for binocular vision. After significant review of literature, it is clear that surgery is the treatment of choice for infantile esotropia but no method has a clear advantage. Efforts to define the best surgical procedure and timing of surgery through prospective, randomized multicenter trials are warranted.
    Current opinion in ophthalmology 07/2015; 26(5):371-4. DOI:10.1097/ICU.0000000000000190